What was the problem?
Patients with G6PD (glucose-6-phosphate dehydrogenase) deficiency are at risk of severe anaemia when treated for malaria. Conventional tests to check for G6PD deficiency are neither cost-effective nor practical for testing at scale in the field, so a point-of-care diagnostic test was a pressing requirement.
To establish suitability for treatment, a new rapid point-of-care diagnostic had to be able to classify patients with either normal, intermediate or deficient G6PD activity levels.
The challenge was to create a diagnostic that could be read visually, operate in environments with high temperatures and humidity, and deliver qualitative results in less than 15 minutes. It needed to be easy to read, cost-effective, and able to be manufactured at scale.
Mologic developed a test incorporating a ‘smart control line’ that indicates if the test has been adversely affected by temperature or if the sample size is insufficient. It incorporated a complex reagent pad, removing the need for refrigeration and allowing for a stable, dry format.
A unique housing was designed to create an equilibrium of test fluids. This prevented over-saturation of the test line and ensured clear test results.
The project resulted in a rapid point-of-care test for diagnosing G6PD deficiency which requires only a 2µl whole blood sample and delivers accurate measurements at a cost of less than $1 per test.
The unitised diagnostic delivers qualitative results which discriminate between normal, intermediate and deficient G6PD activity, indicating suitability for malaria treatment.
It can be used in challenging environments and delivers results in less than 15 minutes.
“The ability to test for G6PD before administering treatment for malaria, increases patient safety and saves lives.”
Public Health Surveillance Advisor